BMC Cancer

Table 3 Univariate analyses of risk factors of pneumothorax in STS patients during pazopanib treatment

From: Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

Pneumothorax	Present (n = 6)		Absent (n = 52)
Variants	No.	%	No.	%	p-value
Gender
Male	5	83	29	56	0.097
Female	1	17	23	44	0.097
Pathological diagnosis
Synovial sarcoma	3	50	6	12	0.042
Others	3	50	46	88	0.042
Hypertension
Present	1	17	9	17	1.00
Absent	5	83	43	83	1.00
Smoking history
Present	3	50	17	33	0.41
Absent	3	50	35	67	0.41
Smoking index ≥ 400
Present	2	33	4	8	0.11
Absent	4	67	48	92	0.11
Lung lesion
Present	6	100	35	67	0.17
Absent	0	0	17	33	0.17
Pleural lesion
Present	4	67	19	37	0.20
Absent	2	33	33	63	0.20
No. of lung lesions
0–1	0	0	29	56	0.072
2 or more	6	100	23	44	0.072
Maximum dia. of lung lesions
≥ 30 mm	5	83	16	31	0.02
< 30 mm	1	17	36	69	0.02
History of lung surgery
Present	2	33	19	37	1.00
Absent	4	67	33	63	1.00
History of pneumothorax
Present	2	33	2	4	0.049
Absent	4	67	50	96	0.049

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com